Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Commercial vs Phase 3 Pimicotinib Capsules
NCT06694948Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimicotinib in tenosynovial giant cell tumor (TGCT) (2 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Plasma Concentration at 240 hours, Area Under the Curve from time zero to infinity at 240 hours and 1 more. Started Dec 2024; status: completed.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT06694948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694948.